Annual CFO
-$181.39 M
-$30.28 M-20.04%
December 31, 2024
Summary
- As of March 12, 2025, XENE annual cash flow from operations is -$181.39 million, with the most recent change of -$30.28 million (-20.04%) on December 31, 2024.
- During the last 3 years, XENE annual CFO has fallen by -$111.89 million (-160.98%).
- XENE annual CFO is now -498.02% below its all-time high of $45.57 million, reached on December 31, 2012.
Performance
XENE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$54.38 M
-$3.24 M-6.33%
December 31, 2024
Summary
- As of March 12, 2025, XENE quarterly cash flow from operations is -$54.38 million, with the most recent change of -$3.24 million (-6.33%) on December 31, 2024.
- Over the past year, XENE quarterly CFO has stayed the same.
- XENE quarterly CFO is now -374.85% below its all-time high of $19.79 million, reached on December 31, 2019.
Performance
XENE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$181.39 M
-$18.98 M-11.69%
December 31, 2024
Summary
- As of March 12, 2025, XENE TTM cash flow from operations is -$181.39 million, with the most recent change of -$18.98 million (-11.69%) on December 31, 2024.
- Over the past year, XENE TTM CFO has stayed the same.
- XENE TTM CFO is now -5738.45% below its all-time high of $3.22 million, reached on September 30, 2014.
Performance
XENE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
XENE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.0% | 0.0% | 0.0% |
| 3 y3 years | -161.0% | -195.1% | -169.8% |
| 5 y5 years | -3747.9% | -195.1% | -169.8% |
XENE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -161.0% | at low | -222.4% | at low | -169.8% | at low |
| 5 y | 5-year | -3747.9% | at low | -374.9% | at low | -3747.9% | at low |
| alltime | all time | -498.0% | at low | -374.9% | at low | -5738.4% | at low |
Xenon Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$181.39 M(+20.0%) | -$54.38 M(+6.3%) | -$181.39 M(+11.7%) |
| Sep 2024 | - | -$51.15 M(+56.5%) | -$162.41 M(+1.9%) |
| Jun 2024 | - | -$32.68 M(-24.3%) | -$159.34 M(-0.3%) |
| Mar 2024 | - | -$43.18 M(+22.0%) | -$159.88 M(+5.8%) |
| Dec 2023 | -$151.11 M(+49.6%) | -$35.40 M(-26.4%) | -$151.11 M(+0.0%) |
| Sep 2023 | - | -$48.08 M(+44.7%) | -$151.04 M(+13.3%) |
| Jun 2023 | - | -$33.22 M(-3.5%) | -$133.36 M(+14.0%) |
| Mar 2023 | - | -$34.41 M(-2.6%) | -$117.01 M(+15.8%) |
| Dec 2022 | -$101.03 M(+45.4%) | -$35.33 M(+16.2%) | -$101.03 M(+16.9%) |
| Sep 2022 | - | -$30.40 M(+80.2%) | -$86.41 M(+21.7%) |
| Jun 2022 | - | -$16.87 M(-8.5%) | -$71.01 M(+5.6%) |
| Mar 2022 | - | -$18.43 M(-11.0%) | -$67.22 M(-3.3%) |
| Dec 2021 | -$69.50 M(+44.4%) | -$20.71 M(+38.0%) | -$69.50 M(+12.3%) |
| Sep 2021 | - | -$15.01 M(+14.8%) | -$61.91 M(+6.6%) |
| Jun 2021 | - | -$13.08 M(-36.9%) | -$58.05 M(+4.1%) |
| Mar 2021 | - | -$20.71 M(+57.9%) | -$55.77 M(+15.9%) |
| Dec 2020 | -$48.12 M(+920.9%) | -$13.11 M(+17.6%) | -$48.12 M(+216.1%) |
| Sep 2020 | - | -$11.15 M(+3.4%) | -$15.22 M(+36.8%) |
| Jun 2020 | - | -$10.79 M(-17.4%) | -$11.13 M(+22.5%) |
| Mar 2020 | - | -$13.07 M(-166.0%) | -$9.09 M(+92.7%) |
| Dec 2019 | -$4.71 M | $19.79 M(-380.3%) | -$4.71 M(-85.1%) |
| Sep 2019 | - | -$7.06 M(-19.3%) | -$31.74 M(-17.4%) |
| Jun 2019 | - | -$8.75 M(+0.6%) | -$38.41 M(+9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$8.70 M(+20.1%) | -$35.20 M(+1.4%) |
| Dec 2018 | -$34.72 M(+20.9%) | -$7.24 M(-47.2%) | -$34.72 M(+1.2%) |
| Sep 2018 | - | -$13.72 M(+147.8%) | -$34.32 M(+17.4%) |
| Jun 2018 | - | -$5.54 M(-32.6%) | -$29.22 M(-4.1%) |
| Mar 2018 | - | -$8.22 M(+20.2%) | -$30.48 M(+6.1%) |
| Dec 2017 | -$28.73 M(+46.8%) | -$6.84 M(-20.7%) | -$28.73 M(+8.2%) |
| Sep 2017 | - | -$8.63 M(+26.8%) | -$26.56 M(+18.3%) |
| Jun 2017 | - | -$6.80 M(+5.3%) | -$22.46 M(+6.5%) |
| Mar 2017 | - | -$6.46 M(+38.3%) | -$21.08 M(+7.7%) |
| Dec 2016 | -$19.57 M(+8.1%) | -$4.67 M(+3.2%) | -$19.57 M(-2.9%) |
| Sep 2016 | - | -$4.52 M(-16.7%) | -$20.14 M(-1.8%) |
| Jun 2016 | - | -$5.43 M(+9.8%) | -$20.50 M(+17.2%) |
| Mar 2016 | - | -$4.94 M(-5.8%) | -$17.50 M(-3.3%) |
| Dec 2015 | -$18.10 M(-6905.6%) | -$5.25 M(+7.4%) | -$18.10 M(+14.5%) |
| Sep 2015 | - | -$4.88 M(+101.5%) | -$15.81 M(+240.8%) |
| Jun 2015 | - | -$2.42 M(-56.3%) | -$4.64 M(+4.5%) |
| Mar 2015 | - | -$5.55 M(+88.0%) | -$4.44 M(-1768.8%) |
| Dec 2014 | $266.00 K(-108.0%) | -$2.95 M(-147.0%) | $266.00 K(-91.7%) |
| Sep 2014 | - | $6.28 M(-382.4%) | $3.22 M(-204.9%) |
| Jun 2014 | - | -$2.23 M(+164.3%) | -$3.07 M(+264.3%) |
| Mar 2014 | - | -$842.00 K | -$842.00 K |
| Dec 2013 | -$3.32 M(-107.3%) | - | - |
| Dec 2012 | $45.57 M(-432.9%) | - | - |
| Dec 2011 | -$13.69 M | - | - |
FAQ
- What is Xenon Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual CFO year-on-year change?
- What is Xenon Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly CFO year-on-year change?
- What is Xenon Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM CFO year-on-year change?
What is Xenon Pharmaceuticals annual cash flow from operations?
The current annual CFO of XENE is -$181.39 M
What is the all time high annual CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual cash flow from operations is $45.57 M
What is Xenon Pharmaceuticals annual CFO year-on-year change?
Over the past year, XENE annual cash flow from operations has changed by -$30.28 M (-20.04%)
What is Xenon Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of XENE is -$54.38 M
What is the all time high quarterly CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly cash flow from operations is $19.79 M
What is Xenon Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, XENE quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Xenon Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of XENE is -$181.39 M
What is the all time high TTM CFO for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM cash flow from operations is $3.22 M
What is Xenon Pharmaceuticals TTM CFO year-on-year change?
Over the past year, XENE TTM cash flow from operations has changed by $0.00 (0.00%)